Fraser Murray

Fraser Murray is the Chief Executive Officer at Pheno Therapeutics Ltd, a company focused on discovering small molecule therapeutics for unmet medical needs. Fraser is also a Co-founder and Scientific Advisor at Pandeia Therapeutics, helping to develop treatments for Huntington's disease. Additionally, Fraser serves as an Investor Director at Tridek-One and Head of Scientific Evaluation at Advent Life Sciences. With a background in Neuroscience and Immunology, Fraser brings expertise to various ventures in the Life Sciences sector.